Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?
A handful of medtechs will benefit from new reimbursement pathways – but others have been denied the chance.
How can the company wring the most value from Pyrukynd?
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.